NUR 210 Exam 1 Principles of Pharmacology
Galen College ACTUAL EXAM 2026/2027 |
Galen NUR 210 Pharm Principles | Verified
Q&A | Pass Guaranteed - A+ Graded
Section 1: Pharmacokinetics (12 Questions)
Q1. A nurse is administering morphine sulfate 4 mg IV to a client in pain. The nurse understands that the
rapid onset of analgesia is primarily due to which pharmacokinetic factor?
A. First-pass metabolism in the liver
B. Immediate absorption into the systemic circulation
C. High protein binding in plasma
D. Extensive distribution to adipose tissue
Correct Answer: B
Rationale: Intravenous administration delivers medication directly into the systemic circulation,
bypassing absorption barriers (GI mucosa, skin, muscle tissue) and achieving 100% bioavailability. This
allows for immediate drug action, with onset typically within 1–5 minutes for IV morphine. First-pass
metabolism (Option A) applies to oral medications absorbed through the portal circulation. Protein
binding (Option C) and adipose distribution (Option D) affect drug duration and elimination, not onset
speed. (ATI Pharmacology Ch. 1 – Pharmacokinetics: IV route provides immediate absorption)
Q2. A client is prescribed propranolol orally for hypertension. The nurse understands that a portion of
the drug will be metabolized by the liver before reaching systemic circulation. Which pharmacokinetic
concept explains this?
A. Volume of distribution
B. First-pass effect
C. Steady-state concentration
D. Therapeutic index
Correct Answer: B
,Rationale: The first-pass effect (first-pass metabolism) occurs when a drug absorbed from the GI tract
travels via the portal vein to the liver, where a significant portion is metabolized before reaching
systemic circulation. This reduces oral bioavailability for highly metabolized drugs like propranolol
(bioavailability ~25%). Nurses must understand that oral doses are often higher than IV doses for the
same drug due to this hepatic extraction. First-pass effect is a critical consideration when switching
routes or assessing why oral medications may have delayed or reduced effects compared to parenteral
administration. (ATI Pharmacology Ch. 1 – First-Pass Effect)
Q3. A nurse is caring for a client with liver cirrhosis who is prescribed lorazepam. Which pharmacokinetic
alteration should the nurse anticipate?
A. Increased drug absorption from the GI tract
B. Decreased drug metabolism and prolonged drug effect
C. Enhanced renal excretion of the active drug
D. Reduced protein binding and increased free drug elimination
Correct Answer: B
Rationale: The liver is the primary site of drug metabolism through the cytochrome P450 enzyme
system. In cirrhosis, hepatocellular damage and reduced blood flow impair CYP450 activity, leading to
decreased metabolism of lorazepam (a benzodiazepine metabolized via hepatic glucuronidation). This
results in prolonged drug half-life, increased drug accumulation, and enhanced sedative effects. The
nurse should anticipate lower starting doses, longer dosing intervals, and enhanced monitoring for
excessive sedation and respiratory depression in clients with hepatic impairment. (ATI Pharmacology Ch.
1 – Hepatic Metabolism Alterations)
Q4. A client is prescribed a medication with a half-life of 8 hours. The nurse understands that
approximately how long will it take for the drug to reach steady-state concentration?
A. 8 hours
B. 16 hours
C. 32–40 hours
D. 80 hours
Correct Answer: C
Rationale: Steady-state concentration (Css) is achieved when the rate of drug administration equals the
rate of elimination, resulting in consistent plasma levels. Pharmacokinetic principles establish that
steady state is reached after approximately 4–5 half-lives. For a drug with an 8-hour half-life: 4 × 8 = 32
hours, and 5 × 8 = 40 hours. Therefore, steady state is achieved between 32–40 hours of consistent
dosing. This concept is critical for understanding why some medications (e.g., warfarin, digoxin,
, antidepressants) require several days to achieve full therapeutic effect and why loading doses may be
used to achieve therapeutic levels more rapidly. (ATI Pharmacology Ch. 1 – Half-Life and Steady State)
Q5. A nurse is administering heparin subcutaneously. The nurse understands that heparin is highly
water-soluble and does not readily cross cell membranes. Which pharmacokinetic parameter explains
why heparin must be given parenterally?
A. Low bioavailability due to first-pass metabolism and poor GI absorption
B. High volume of distribution requiring large injection volumes
C. Extensive protein binding preventing systemic distribution
D. Rapid renal excretion preventing oral absorption
Correct Answer: A
Rationale: Heparin is a large, highly polar, water-soluble molecule that cannot be absorbed from the
gastrointestinal tract due to its inability to cross lipid membranes of intestinal epithelial cells.
Additionally, heparin would be inactivated by gastric acid and digestive enzymes. Therefore, heparin
must be administered parenterally (IV or subcutaneous) to achieve therapeutic anticoagulation. The
nurse must understand that oral administration of heparin would result in negligible systemic
absorption and therapeutic failure. Low molecular weight heparins (enoxaparin) share this characteristic
and are also administered subcutaneously. (ATI Pharmacology Ch. 1 – Route Selection Based on Drug
Properties)
Q6. A client with chronic kidney disease (CKD) stage 4 is prescribed gabapentin. The nurse understands
that which pharmacokinetic parameter requires dose adjustment?
A. Absorption from the GI tract
B. Distribution to the central nervous system
C. Renal excretion of unchanged drug
D. Hepatic metabolism via CYP450 enzymes
Correct Answer: C
Rationale: Gabapentin is eliminated almost entirely by renal excretion as unchanged drug, with
negligible hepatic metabolism. In CKD stage 4 (eGFR 15–29 mL/min), renal clearance is severely
impaired, leading to drug accumulation, increased half-life, and enhanced risk of adverse effects
(sedation, dizziness, ataxia, peripheral edema). The nurse must anticipate dose reduction (typically 50%
reduction for eGFR <30) and extended dosing intervals. Renally cleared drugs requiring dose adjustment
in CKD include gabapentin, pregabalin, vancomycin, aminoglycosides, digoxin, and many others.
Monitoring renal function and drug levels (when applicable) is essential for safe medication
management. (ATI Pharmacology Ch. 1 – Renal Excretion and Dose Adjustment)
Galen College ACTUAL EXAM 2026/2027 |
Galen NUR 210 Pharm Principles | Verified
Q&A | Pass Guaranteed - A+ Graded
Section 1: Pharmacokinetics (12 Questions)
Q1. A nurse is administering morphine sulfate 4 mg IV to a client in pain. The nurse understands that the
rapid onset of analgesia is primarily due to which pharmacokinetic factor?
A. First-pass metabolism in the liver
B. Immediate absorption into the systemic circulation
C. High protein binding in plasma
D. Extensive distribution to adipose tissue
Correct Answer: B
Rationale: Intravenous administration delivers medication directly into the systemic circulation,
bypassing absorption barriers (GI mucosa, skin, muscle tissue) and achieving 100% bioavailability. This
allows for immediate drug action, with onset typically within 1–5 minutes for IV morphine. First-pass
metabolism (Option A) applies to oral medications absorbed through the portal circulation. Protein
binding (Option C) and adipose distribution (Option D) affect drug duration and elimination, not onset
speed. (ATI Pharmacology Ch. 1 – Pharmacokinetics: IV route provides immediate absorption)
Q2. A client is prescribed propranolol orally for hypertension. The nurse understands that a portion of
the drug will be metabolized by the liver before reaching systemic circulation. Which pharmacokinetic
concept explains this?
A. Volume of distribution
B. First-pass effect
C. Steady-state concentration
D. Therapeutic index
Correct Answer: B
,Rationale: The first-pass effect (first-pass metabolism) occurs when a drug absorbed from the GI tract
travels via the portal vein to the liver, where a significant portion is metabolized before reaching
systemic circulation. This reduces oral bioavailability for highly metabolized drugs like propranolol
(bioavailability ~25%). Nurses must understand that oral doses are often higher than IV doses for the
same drug due to this hepatic extraction. First-pass effect is a critical consideration when switching
routes or assessing why oral medications may have delayed or reduced effects compared to parenteral
administration. (ATI Pharmacology Ch. 1 – First-Pass Effect)
Q3. A nurse is caring for a client with liver cirrhosis who is prescribed lorazepam. Which pharmacokinetic
alteration should the nurse anticipate?
A. Increased drug absorption from the GI tract
B. Decreased drug metabolism and prolonged drug effect
C. Enhanced renal excretion of the active drug
D. Reduced protein binding and increased free drug elimination
Correct Answer: B
Rationale: The liver is the primary site of drug metabolism through the cytochrome P450 enzyme
system. In cirrhosis, hepatocellular damage and reduced blood flow impair CYP450 activity, leading to
decreased metabolism of lorazepam (a benzodiazepine metabolized via hepatic glucuronidation). This
results in prolonged drug half-life, increased drug accumulation, and enhanced sedative effects. The
nurse should anticipate lower starting doses, longer dosing intervals, and enhanced monitoring for
excessive sedation and respiratory depression in clients with hepatic impairment. (ATI Pharmacology Ch.
1 – Hepatic Metabolism Alterations)
Q4. A client is prescribed a medication with a half-life of 8 hours. The nurse understands that
approximately how long will it take for the drug to reach steady-state concentration?
A. 8 hours
B. 16 hours
C. 32–40 hours
D. 80 hours
Correct Answer: C
Rationale: Steady-state concentration (Css) is achieved when the rate of drug administration equals the
rate of elimination, resulting in consistent plasma levels. Pharmacokinetic principles establish that
steady state is reached after approximately 4–5 half-lives. For a drug with an 8-hour half-life: 4 × 8 = 32
hours, and 5 × 8 = 40 hours. Therefore, steady state is achieved between 32–40 hours of consistent
dosing. This concept is critical for understanding why some medications (e.g., warfarin, digoxin,
, antidepressants) require several days to achieve full therapeutic effect and why loading doses may be
used to achieve therapeutic levels more rapidly. (ATI Pharmacology Ch. 1 – Half-Life and Steady State)
Q5. A nurse is administering heparin subcutaneously. The nurse understands that heparin is highly
water-soluble and does not readily cross cell membranes. Which pharmacokinetic parameter explains
why heparin must be given parenterally?
A. Low bioavailability due to first-pass metabolism and poor GI absorption
B. High volume of distribution requiring large injection volumes
C. Extensive protein binding preventing systemic distribution
D. Rapid renal excretion preventing oral absorption
Correct Answer: A
Rationale: Heparin is a large, highly polar, water-soluble molecule that cannot be absorbed from the
gastrointestinal tract due to its inability to cross lipid membranes of intestinal epithelial cells.
Additionally, heparin would be inactivated by gastric acid and digestive enzymes. Therefore, heparin
must be administered parenterally (IV or subcutaneous) to achieve therapeutic anticoagulation. The
nurse must understand that oral administration of heparin would result in negligible systemic
absorption and therapeutic failure. Low molecular weight heparins (enoxaparin) share this characteristic
and are also administered subcutaneously. (ATI Pharmacology Ch. 1 – Route Selection Based on Drug
Properties)
Q6. A client with chronic kidney disease (CKD) stage 4 is prescribed gabapentin. The nurse understands
that which pharmacokinetic parameter requires dose adjustment?
A. Absorption from the GI tract
B. Distribution to the central nervous system
C. Renal excretion of unchanged drug
D. Hepatic metabolism via CYP450 enzymes
Correct Answer: C
Rationale: Gabapentin is eliminated almost entirely by renal excretion as unchanged drug, with
negligible hepatic metabolism. In CKD stage 4 (eGFR 15–29 mL/min), renal clearance is severely
impaired, leading to drug accumulation, increased half-life, and enhanced risk of adverse effects
(sedation, dizziness, ataxia, peripheral edema). The nurse must anticipate dose reduction (typically 50%
reduction for eGFR <30) and extended dosing intervals. Renally cleared drugs requiring dose adjustment
in CKD include gabapentin, pregabalin, vancomycin, aminoglycosides, digoxin, and many others.
Monitoring renal function and drug levels (when applicable) is essential for safe medication
management. (ATI Pharmacology Ch. 1 – Renal Excretion and Dose Adjustment)
